Clinical and functional efficacy of the antileukotriene agent montelucast (singulair) was investigated in 30 patients with moderately severe bronchial asthma. Patients with a positive FEV1 response to montelukast (61.1%) demonstrated a higher blood level of IgE and sputum eosinophilia. Enhancement of bronchodilatatory effect secondary to the use of beta 2-agonist has been recordable in the wake of a 24-day montelucast treatment (10 mg o.d.).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
bronchial asthma
8
[clinical study
4
study anti-leukotriene
4
anti-leukotriene therapy
4
therapy montelukast
4
montelukast bronchial
4
asthma patients]
4
patients] clinical
4
clinical functional
4
functional efficacy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!